MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotheraphy

Neoplasia

Volumn 12, Issue 8, 2010, Pages 628-636

  Hoffmann, Andreas Claudius ^a,b,c   Wild, Peter ^d   Leicht, Christina ^e   Bertz, Simone ^f   Danenberg, Kathleen D ^c   Danenberg, Peter V ^b   Stöhr, Robert ^f   Stöckle, Michael ^g   Lehmann, Jan ^h   Schuler, Martin ^a   Hartmann, Arndt ^f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Response Genetics Inc   (United States)

^d ETH ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h Urology Practice Prüner Gang   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CISPLATIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; RNA; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE FIXATION;

EID: 77956044313     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10402     Document Type: Article

References (38)

1. Freiha F, Reese J, and Torti FM (1996). A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155, 495-499; discussion 499-500.
2. Stockle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thuroff JW, Huber C, and Hohenfellner R (1995). Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153, 47-52.
3. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, and Groshen S (1991). The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative ial. J Urol 145, 459-464; discussion 464-467.
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, et al. (1985). Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133, 403-407.
5. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, and Kilbourn RG (1990). A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8, 1050-1055.
6. Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, et al. (2005). Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23, 4963-4974.
7. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, et al. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16, 309-316.
8. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, et al. (2007). Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatinbased chemotherapy. Ann Oncol 18, 522-528.
9. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, et al. (2007). Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25, 2747-2754.
10. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, et al. (2007). Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25, 2741-2746.
11. de Graaf D, Sharma RC, Mechetner EB, Schimke RT, and Roninson IB (1996). P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carriermediated methotrexate uptake. Proc Natl Acad Sci USA 93, 1238-1242.
12. Pastan I, Willingham MC, and Gottesman M(1991).Molecular manipulations of the multidrug transporter: a new role for transgenic mice. FASEB J 5, 2523-2528.
13. Walter RB, Gooley TA, van derVelden VH, Loken MR, vanDongen JJ, Flowers DA, Bernstein ID, and Appelbaum FR (2007). CD33 expression and P-glycoprotein- mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109, 4168-4170.
14. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, and Linenberger ML (2003). Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102, 1466-1473.
15. Pallis M and Russell N (2000). P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95, 2897-2904.
16. Ashariati A (2008). Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med Indones 40, 187-191.
17. Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, and Mirossay A (2010). MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 10(1), 62-69.
18. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, and Scotto KW (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5, 3352-3356.
19. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, et al. (1995). Expression of Pglycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333, 1380-1385.
20. Goebell PJ (2009). Outcomes and response to therapy in bladder cancer. Are biomarkers of any help? Minerva Urol Nefrol 61, 91-107.
21. Petrylak DP, Scher HI, Reuter V, O'Brien JP, and Cordon-Cardo C (1994). P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5, 835-840.
22. Sobin LH and Fleming ID (1997). TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80, 1803-1804.
23. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, and Wuerl P (2009). A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 15, 5191-5198.
24. Somlo G, Chu P, Frankel P, Ye W, Groshen S, Doroshow JH, Danenberg K, and Danenberg P (2008). Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol 19, 1853-1859.
25. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, et al. (2008). High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10, 674-679.
26. Metz CE (1978). Basic principles of ROC analysis. Semin Nucl Med 8, 283-298.
27. Zweig MH and Campbell G (1993). Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39, 561-577.
28. Angulo JC, Lopez JI, Grignon DJ, and Sanchez-Chapado M (1995). Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 45, 47-53.
29. Lehmann J, Franzaring L, Thuroff J, Wellek S, and Stockle M (2006). Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 97, 42-47.
30. Demeule M, Brossard M, and Beliveau R (1999). Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol 277, F832-F840.
31. Takara K, Tsujimoto M, Kokufu M, Ohnishi N, and Yokoyama T (2003). Upregulation of MDR1 function and expression by cisplatin in LLC-PK1 cells. Biol Pharm Bull 26, 205-209.
32. van den Broek GB, Wildeman M, Rasch CR, Armstrong N, Schuuring E, Begg AC, Looijenga LH, Scheper R, van der Wal JE, Menkema L, et al. (2009). Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124, 2643-2650.
33. Pu YS, Tsai TC, Cheng AL, Tsai CY, Tseng NF, Su IJ, Hsieh CY, and Lai MK (1996). Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response. J Urol 156, 271-275.
34. Ren L, Xiao L, and Hu J (2007). MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci 27, 721-724.
35. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, and Dinney CP (2009). Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 27, 5680-5684.
36. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, et al. (2003). Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349, 859-866.
37. International Collaboration of Trialists (1999). Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354, 533-540.
38. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, Dunn J, Boulas J, and Latief T (1991). Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67, 608-615.